EMA Authorised: Lyumjev (previously Liumjev) (insulin lispro) — Eli Lilly Nederland B.V.

View source ↗

Summary

EMA authorised Lyumjev (insulin lispro) by Eli Lilly Nederland B.V. for the treatment of diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Lyumjev (insulin lispro)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Eli Lilly Nederland B.V.. Decision date: 21/01/2026